Mizuho Upgrades Valeant, Says Financial Engineering Helped Company 'Outfox The Shorts'

By: via Benzinga
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) reported Q2 results with the revenue and EPS missing expectations. Mizuho’s Irina ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.